


Available online at www.sciencedirect.com

ScienceDirect

journal homepage: http://www.journals.elsevier.com/ indian-journal-of-tuberculosis/



Case Report

Multidrug-resistant tuberculosis among different types of suspected cases: Study from New Delhi

Ritu Singhal^a, Neeta Singla^b, Vithal Prasad Myneedu^{c,*}, Niti Singh^d, Rohit Sarin^e

ARTICLE INFO

Article history: Received 30 July 2014 Accepted 8 July 2015 Available online 4 November 2015

Keywords: Multi-drug resistance Line probe assay Mycobacterium

ABSTRACT

There are limited data of multidrug-resistant tuberculosis (MDR-TB) diagnosed in various patient categories by implementing Programmatic Management of Drug Resistant TB (PMDT) using line probe assay (LPA) from our country. Samples from presumptive MDR-TB from five districts of New Delhi were subjected to LPA from 1st October 2011 to 31st December 2014. The MDR-TB diagnosed in 4th & 5th month follow-up positives were significantly higher than other categories of the patients. Only 3/232 (2.2%) RIF resistants were diagnosed among smear negative re-treatment cases. The data suggest interim costbenefit analysis of the program especially among smear negatives retreatment cases.

© 2015 Published by Elsevier B.V. on behalf of Tuberculosis Association of India.

1. Introduction

Multidrug-resistant tuberculosis (MDR-TB) defined as the resistance to at-least rifampicin (RIF) and isoniazid (INH) has become a significant public health problem due to prolonged and expensive treatment resulting in failure and death.¹ Based on drug resistance surveillance studies conducted in 2006–2008, estimated proportion of MDR-TB is 2.1% (1.5–2.7%) and 15% (13%–17%), in new and retreatment cases respectively.²

India had launched PMDT under Revised National Tuberculosis Control Programme (RNTCP) in 2011, in which notified TB patients are identified as "presumptive MDR-TB" based on pre-decided "Criteria" and are further diagnosed for MDR-TB by rapid method.³ Criterion A includes new TB cases smear positive at 5th month of treatment, retreatment cases smear positive at 4th month, and all TB contacts of diagnosed MDR-TB case. Criterion B includes all smear positive re-treatment PTB cases at diagnosis or follow-up and any smear positive follow-up in Category I (Smear +ve at 2 months of treatment or later) in addition to Criterion A. Criterion C includes all smear negative re-treatment TB cases and HIV-TB co-infected cases, in addition to Criterion B.³ All RIF resistants are started with category IV treatment irrespective of INH

E-mail address: vpm_myn@hotmail.com (V.P. Myneedu). http://dx.doi.org/10.1016/j.ijtb.2015.09.004

^a Specialist Microbiology, Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, India

^b Senior Research Officer, Department of Epidemiology, National Institute of Tuberculosis and Respiratory Diseases, India

^c Head of Department, Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, India

^d NRL Microbiologist, Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, India

^e Director of the Institute, National Institute of Tuberculosis and Respiratory Diseases, India

^{*} Corresponding author at: HOD Microbiology, National Institute of Tuberculosis and Respiratory Diseases, Aurobindo Marg, New Delhi 110030, India. Tel.: +91 9871731307.

Year	Clinical type		Follow up positive at end of 5th month and 4th month, CAT I and CAT II respectively			Follow up positive at end of IP			MDR-TB contacts	CAT II entry smear positive	CAT II entry smear negative	HIV positive	Total
			CAT I, 5th month	CAT II, 4th month	TOTAL	CAT I, end of IP	CAT II, end of IP	Total		F			
2011	MDR suspects		40	101	141				1				142
	RIF resistance	No.	14	35	49				0				49
		%	35.00%	34.70%	34.50%								34.50
	MDR	No.	13	30	43				0				43
		%	32.50%	29.70%	30.50%								30.30
	INH resistance	No.	17	33	50				0				50
		%	42.50%	32.70%	35.50%								35.20
2012	MDR suspects					800	421	1221	0	1160	47		2430
	RIF resistance	No.				122	60	182	0	175	1		358
		%				15.20%	14.30%	14.90%		15.10%	2.10%		14.70
	MDR	No.				94	49	143	0	136	1		280
		%				11.80%	11.60%	11.70%		11.70%	2.10%		11.50
	INH resistance	No.				127	80	207	0	187	1		395
		%				15.90%	19.00%	16.90%		16.10%	2.10%		16.30
2013	MDR suspects					673	320	993	5	1053	139	11	2201
	RIF resistance	No.				83	38	121	2	168	2	0	293
		%				12.30%	11.90%	12.20%	40.00%	15.60%	1.40%	0	13.30
	MDR	No.				75	33	108	2	131	2	0	230
		%				11.10%	10.30%	10.90%	40.00%	12.40%	1.40%	0.00%	10.40
	INH resistance	No.				118	48	166	4	191	4	1	366
		%				17.50%	15.00%	16.70%	80.00%	18.10%	2.90%	9.10%	16.60
2014	MDR suspects					348	192	540	13	690	46	7	1296
	RIF resistance	No.				41	30	71	4	94	0	2	171
		%				11.80%	15.60%	13.10%	30.80%	13.60%	0.00%	0.00%	13.20
	MDR	No.				35	20	55	4	72	0	2	133
		%				10.10%	10.40%	10.20%	30.80%	10.40%	0.00%	0.00%	10.30
	INH resistance	No.				64	38	102	5	140	0	4	251
		%				18.40%	20.00%	18.90%	38.50%	20.30%	0	0	19.40
Total	MDR suspects		40	101	141	1821	933	2754	18	2903	232	18	6066
	RIF resistance	No.	14	35	49	246	128	374	6	437	3	2	871
		%	35.00%	34.70%	34.50%	13.50%	13.70%	13.60%	33.30%	15.10%	1.30%	11.10%	14.40
	MDR	No.	13	30	43	210	102	312	6	339	3	2	705
		%	32.50%	29.70%	30.50%	11.50%	10.90%	11.30%	33.30%	11.70%	1.30%	11.10%	11.60
	INH resistance	No.	17	33	50	309	166	475	9	518	5	5	1062
		%	42.50%	32.70%	35.50%	16.70%	17.80%	17.20%	50.00%	17.80%	2.20%	27.80%	17.50

MDR-TB: Multi-drug resistant tuberculosis; CAT: Category; RIF: Rifampicin; INH: Isoniazid.

Download English Version:

https://daneshyari.com/en/article/3403506

Download Persian Version:

https://daneshyari.com/article/3403506

<u>Daneshyari.com</u>